In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vatrix Medical Inc.

www.vatrixmedical.com

Latest From Vatrix Medical Inc.

EVAR Market: Challenges, Innovation and Growth

Endovascular aortic aneurysm repair procedures account for the majority of abdominal aortic aneurysm repairs performed in the US, and total worldwide revenues from aortic endograft systems now exceed $1 billion per year. Many believe that continuing improvements in endograft technology will drive EVAR penetration to 90% or beyond within the next five to 10 years. This article first appeared in the April issue of Medtech Insight, April 2011.

EVAR Market: Challenges, Innovation and Growth

Endovascular aortic aneurysm repair procedures account for the majority of abdominal aortic aneurysm repairs performed in the US, and total worldwide revenues from aortic endograft systems now exceed $1 billion per year. Many believe that continuing improvements in endograft technology will drive EVAR penetration to 90% or beyond within the next five to 10 years. However, before that milestone is reached, the field must address a number of lingering concerns about long-term endograft stability and viability, and endograft systems will need to evolve to encompass a wider range of patients with challenging anatomy, including small or tortuous access vessels, short or highly angulated aortic necks, and aneurysms that lie close to the renal arteries.
Medical Device

Vatrix Medical Inc.

Early detection of abdominal aortic aneurysms - which are associated with degradation of the artery and result in weakening and expansion of the blood vessel that can lead to an often-fatal rupture - appears promising with a simple urine test being developed by Vatrix Medical Inc. The start-up is also introducing a minimally invasive endovascular procedure to slow AAA growth by treating the aneurysmal tissue with a novel class of stabilizing agents that bind directly to the diseased artery.
Medical Device

Start-Up Previews (03/2010)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Transdermal Drug Delivery: More Than Skin Deep, features profiles of AllTranz, Ocelus, Quinnova and Syntropharma. Plus these Start-Ups Across Health Care: Apnex Medical, Cellular Dynamics, Helix Therapeutics, Presym and Vatrix Medical.
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Urine-based Testing
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Vatrix Medical Inc.
  • Senior Management
  • Matthew Ogle, CEO
  • Contact Info
  • Vatrix Medical Inc.
    Phone: (612) 381-7674
    7600 Executive Dr.
    Eden Prairie, MN 55344
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register